-
Barclays Analyst Pens Open Letter To Gilead Board And Management
Friday, March 10, 2017 - 11:22am | 376On Friday, Barclays analyst Geoff Meacham veered from his typical approach of addressing clients and chose to speak directly to management at Gilead Sciences, Inc. (NASDAQ: GILD). Meacham chose to structure his latest research note on the pharma giant as a letter to the company, which included five...
-
Barclays Sees 40% Upside In Versartis Over Next Year
Thursday, March 9, 2017 - 10:14am | 308Barclays’ Geoff Meacham expects Versartis Inc (NASDAQ: VSAR) to report “pivotal phase 3 data of somavaratan in pediatric growth hormone deficient (GHD) patients by September 2017.” The analyst initiated coverage of the company with an Overweight rating and price target of $28....
-
Which Pharma Players Dominate The Lung Cancer Space?
Wednesday, January 25, 2017 - 3:40pm | 946Lung and bronchus cancer is the leading cause of cancer deaths in the United States, according to the National Cancer Institute. Lung cancer is of two types, namely non-small cell lung cancer, or NSCLC and small cell lung cancer, or SCLC, with the former more prevalent than the latter. Estimates by...
-
Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion
Tuesday, November 29, 2016 - 11:39am | 734Biopharma companies are poised to benefit from U.S. tax reform related to repatriation of OUS (Outside the United States) cash or a rate change, as well as a lower priority being given to drug pricing reform, Barclays’ Geoff Meacham said in a report. He added, however, that biopharma stocks...
-
Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment
Monday, October 10, 2016 - 10:25am | 292Merck & Co., Inc. (NYSE: MRK) shares are pushing higher by 1.9 percent on Monday following the company’s encouraging new data on Keytruda. On Sunday, Merck reported that Keytruda reduced patient deaths by 40 percent compared to chemotherapy alone and cut disease progression in half....
-
Alnylam Has Had Its Share Of Recent Pipeline Setbacks; Barclays Cuts PT To $50
Thursday, October 6, 2016 - 8:44am | 282Given the discontinuation of the Revusiran program on Wednesday, delays in the ATT program and additional work required for the complement program, Barclays’ Geoff Meacham noted that Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has seen several recent pipeline setbacks. Meacham downgraded...
-
Kite Pharma's Initial ZUMA Data 'Solid'; Barclays Raises Target To $65
Tuesday, September 27, 2016 - 1:38pm | 394A day after Kite Pharma Inc (NASDAQ: KITE) reported positive results from its interim analysis of ZUMA-1 for KTE-C19, which met its primary endpoint, Barclays lifted the target price from $60 to $65 on the company's shares. This implied about 18 percent upside potentials from Monday's closing price...
-
Barclays Raises Target On Merck, Lowers Target On Bristol-Myers
Friday, September 9, 2016 - 9:56am | 325While immuno-oncology [I-O] would eventually be a combination therapy market, this could take a long time, Barclays’ Geoff Meacham said in a report. He added that neither Bristol-Myers Squibb Co (NYSE: BMY) nor Merck & Co., Inc. (NYSE: MRK) deserved full credit “until the clinical...
-
Barclay Reviews Pfizer's Second Quarter, Maintains $34 Target
Tuesday, August 2, 2016 - 10:39am | 312Pfizer Inc. (NYSE: PFE) reported 2Q16 results, with the total revenue beating the consensus by 1 percent but U.S. revenue missing the consensus by 2 percent. Barclays’ Geoff Meacham maintained an Equal-Weight rating on the company, with a price target of $34. Meacham mentioned that the...
-
In Barclays' View, 2016's Second Half Looks 'Noisy' For AbbVie
Monday, August 1, 2016 - 11:30am | 389AbbVie Inc (NYSE: ABBV) reported another beat and raise quarter, with the 2Q revenue and EPS beating the consensus expectations. Barclays’ Geoff Meacham maintains an Equal-Weight rating on the company, with a price target of $68. Meacham mentioned that while execution remains consistent, 2H16...
-
Barclays Says Acceleration For Amgen Could Be A Challenge
Thursday, July 28, 2016 - 11:18am | 432Amgen, Inc. (NASDAQ: AMGN) reported robust 2Q results on both the top and bottom lines, modestly beating expectations. Barclays’ Geoff Meacham maintained an Equal-Weight rating on the company, with a price target of $185. Further Acceleration Could Be Challenging “While we have fairly...
-
Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings
Wednesday, July 27, 2016 - 9:12am | 379Barclays remains Overweight on Gilead Sciences, Inc. (NASDAQ: GILD) on valuation and franchise stability, despite reporting disappointing second-quarter results on the heels of hepatitis C drug Harvoni's continued sales declines. Harvoni, Sovaldi Sales for Harvoni plunged about 29 percent to $2.56...
-
Medivation Prescription Growth And Potential Price Increases Could Drive Upside This Year
Thursday, June 16, 2016 - 10:17am | 311Medivation Inc (NASDAQ: MDVN) is in the limelight given the ongoing takeover by Sanofi SA (ADR) (NYSE: SNY), which is expected to gain momentum into the end of the solicitation period in early August. Barclays' Geoff Meacham maintained an Overweight rating for Medivation, with a price target...
-
Barclays Cuts Alexion Pharmaceuticals Target From $180 To $165
Tuesday, June 7, 2016 - 1:13pm | 320Barclays cut the estimates and price target of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) after its phase 3 data for Soliris in myasthenia gravis (gMG) missed statistical significance on the primary endpoint. The brokerage has conservatively eliminated all MG sales from its model, thus...
-
There's Hope For BioMarin Beyond Kyndrisa
Friday, June 3, 2016 - 9:36am | 252BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced it has withdrawn Kyndrisa’s marketing authorization application in the EU, following expectations of a negative opinion from CHMP. Barclays’ Geoff Meacham maintained an Overweight rating on the company, with a price target of $...